249 related articles for article (PubMed ID: 18310316)
1. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
[TBL] [Abstract][Full Text] [Related]
2. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
Wang G; Dombkowski A; Chuang L; Xu XX
Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
[TBL] [Abstract][Full Text] [Related]
3. The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells.
Luu Y; Li G
Anticancer Res; 2003; 23(1A):99-105. PubMed ID: 12680200
[TBL] [Abstract][Full Text] [Related]
4. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 isoforms in renal cell carcinoma.
Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ
Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415
[TBL] [Abstract][Full Text] [Related]
6. Expression of C-terminal deleted p53 isoforms in neuroblastoma.
Goldschneider D; Horvilleur E; Plassa LF; Guillaud-Bataille M; Million K; Wittmer-Dupret E; Danglot G; de Thé H; Bénard J; May E; Douc-Rasy S
Nucleic Acids Res; 2006; 34(19):5603-12. PubMed ID: 17028100
[TBL] [Abstract][Full Text] [Related]
7. Nucleotide excision repair gene expression after Cisplatin treatment in melanoma.
Bowden NA; Ashton KA; Avery-Kiejda KA; Zhang XD; Hersey P; Scott RJ
Cancer Res; 2010 Oct; 70(20):7918-26. PubMed ID: 20807809
[TBL] [Abstract][Full Text] [Related]
8. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
[TBL] [Abstract][Full Text] [Related]
9. Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells.
An SH; Kang JH; Kim DH; Lee MS
BMB Rep; 2011 Mar; 44(3):211-6. PubMed ID: 21429301
[TBL] [Abstract][Full Text] [Related]
10. Candidate genes for cross-resistance against DNA-damaging drugs.
Wittig R; Nessling M; Will RD; Mollenhauer J; Salowsky R; Münstermann E; Schick M; Helmbach H; Gschwendt B; Korn B; Kioschis P; Lichter P; Schadendorf D; Poustka A
Cancer Res; 2002 Nov; 62(22):6698-705. PubMed ID: 12438269
[TBL] [Abstract][Full Text] [Related]
11. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
Asada N; Tsuchiya H; Tomita K
Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
[TBL] [Abstract][Full Text] [Related]
12. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
13. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
Beuvink I; Boulay A; Fumagalli S; Zilbermann F; Ruetz S; O'Reilly T; Natt F; Hall J; Lane HA; Thomas G
Cell; 2005 Mar; 120(6):747-59. PubMed ID: 15797377
[TBL] [Abstract][Full Text] [Related]
14. Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells.
Zacal N; Espiritu M; Singh G; Rainbow AJ
Biochem Biophys Res Commun; 2005 Jun; 331(2):648-57. PubMed ID: 15850808
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of ASK/Dbf4 in cutaneous melanoma is dependent on E2F1.
Nambiar S; Mirmohammadsadegh A; Hassan M; Hegemann JH; Hengge UR
Exp Dermatol; 2008 Dec; 17(12):986-91. PubMed ID: 18503552
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
17. Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis.
Maxwell SA; Roth JA; Mukhopadhyay T
Electrophoresis; 1996 Nov; 17(11):1772-5. PubMed ID: 8982610
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the functional integrity of the p53 tumor-suppressor gene in malignant melanoma.
Knopf A; Plettenberg C; Pickhard A; Bas M; Reifenberger J; Bier H; Balz V
Melanoma Res; 2011 Oct; 21(5):380-8. PubMed ID: 21691232
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
